{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:14:42Z","timestamp":1792782882224,"version":"4.5.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte (BfArM)","id":[{"id":"https:\/\/ror.org\/05ex5vz81","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Child Adolesc Psychiatry"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s00787-026-03031-5","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T12:11:35Z","timestamp":1777291895000},"page":"2593-2605","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prescribing trends and spontaneous reporting patterns of adverse drug reactions of ADHD medications in children and adolescents in germany: A retrospective analysis (2013\u20132022)"],"prefix":"10.1007","volume":"35","author":[{"given":"Diana","family":"Dubrall","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Reifferscheid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Egberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Fekete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antje","family":"Neubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans W","family":"Rock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Plener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maike","family":"Below","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Romanos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhardt","family":"Sachs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,27]]},"reference":[{"key":"3031_CR1","unstructured":"AWMF online. Portal der wissenschaftlichen Medizin. S3-Leitlinie ADHS bei Kindern, Jugendlichen und Erwachsenen (2017) https:\/\/register.awmf.org\/de\/leitlinien\/detail\/028-045. Accessed 18 December 2025"},{"issue":"3","key":"3031_CR2","doi-asserted-by":"publisher","first-page":"42","DOI":"10.17886\/RKI-GBE-2018-085","volume":"19","author":"K G\u00f6bel","year":"2018","unstructured":"G\u00f6bel K, Baumgarten F, Kuntz B, H\u00f6lling H, Schlack R (2018) ADHD in children and adolescents in Germany. Results of the cross-sectional KiGGS Wave 2 study and trends. J Health Monit 19(3):42\u201349. https:\/\/doi.org\/10.17886\/RKI-GBE-2018-085","journal-title":"J Health Monit"},{"key":"3031_CR3","unstructured":"Federal Joint Committee. Directive on the prescription of pharmaceuticals in statutory health care (2025) https:\/\/www.g-ba.de\/english. Accessed 18 December 2025"},{"issue":"1","key":"3031_CR4","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1186\/s12888-021-03409-6","volume":"14","author":"MK Akmatov","year":"2021","unstructured":"Akmatov MK, Holstiege J, B\u00e4tzing J (2021) Secular trends and regional variations in pharmacotherapy of attention-deficit\/hyperactivity disorder (ADHD) among children and adolescents in Germany. BMC Psychiatry 14(1):405. https:\/\/doi.org\/10.1186\/s12888-021-03409-6","journal-title":"BMC Psychiatry"},{"issue":"1","key":"3031_CR5","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s00228-020-02948-3","volume":"77","author":"T Grimmsmann","year":"2021","unstructured":"Grimmsmann T, Himmel W (2021) The 10-year trend in drug prescriptions for attention-deficit\/hyperactivity disorder (ADHD) in Germany. Eur J Clin Pharmacol 77(1):107\u2013115. https:\/\/doi.org\/10.1007\/s00228-020-02948-3","journal-title":"Eur J Clin Pharmacol"},{"issue":"5","key":"3031_CR6","doi-asserted-by":"publisher","first-page":"CD012069","DOI":"10.1002\/14651858.CD012069.pub2","volume":"9","author":"OJ Storeb\u00f8","year":"2018","unstructured":"Storeb\u00f8 OJ, Pedersen N, Ramstad E, Kielsholm ML, Nielsen SS, Krogh HB, Moreira-Maia CR, Magnusson FL, Holmskov M, Gerner T, Skoog M, Rosendal S, Groth C, Gillies D, Buch Rasmussen K, Gauci D, Zwi M, Kirubakaran R, H\u00e5konsen SJ, Aagaard L, Simonsen E, Gluud C (2018) Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of adverse events in non-randomised studies. Cochrane Database Syst Rev 9(5):CD012069. https:\/\/doi.org\/10.1002\/14651858.CD012069.pub2","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"3031_CR7","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s40360-021-00520-y","volume":"7","author":"D Dubrall","year":"2021","unstructured":"Dubrall D, Leitzen S, Toni I, Stingl J, Schulz M, Schmid M, Neubert A, Sachs B (2021) Descriptive analysis of adverse drug reaction reports in children and adolescents from Germany: frequently reported reactions and suspected drugs. BMC Pharmacol Toxicol 7(1):56. https:\/\/doi.org\/10.1186\/s40360-021-00520-y","journal-title":"BMC Pharmacol Toxicol"},{"key":"3031_CR8","unstructured":"Strattera (2005) Warnhinweis auf suizidales Verhalten bei Kindern mit ADHS angeordnet https:\/\/www.bfarm.de\/SharedDocs\/Pressemitteilungen\/DE\/mitteil-alt\/pm18-2005.html. Accessed 18 December 2025"},{"key":"3031_CR9","unstructured":"Methylphenidathaltige Arzneimittel: Artikel 31-Verfahren (2009) https:\/\/www.bfarm.de\/SharedDocs\/Risikoinformationen\/Pharmakovigilanz\/DE\/RV_STP\/m-r\/methylphenidat.html. Accessed 18 December 2025"},{"key":"3031_CR10","unstructured":"WICHTIGE SICHERHEITSRELEVANTE INFORMATION ZU STRATTERA (ATOMOXETIN) UND DES RISIKOS EINES BLUTDRUCK- UND HERZFREQUENZANSTIEGS (2011) https:\/\/www.bfarm.de\/SharedDocs\/Risikoinformationen\/Pharmakovigilanz\/DE\/RHB\/2011\/rhb-strattera.pdf?__blob=publicationFile. Accessed 18 December 2025"},{"key":"3031_CR11","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s40268-024-00499-x","volume":"25","author":"D Dubrall","year":"2025","unstructured":"Dubrall D, Wicherski J, Below M et al (2025) Analyses of Adverse Drug Reactions to Fluoroquinolones in Spontaneous Reports Before and After the Referral and in Clinical Routine Cases. Drugs R D 25:35\u201355. https:\/\/doi.org\/10.1007\/s40268-024-00499-x","journal-title":"Drugs R D"},{"key":"3031_CR12","unstructured":"Zentralinstitut f\u00fcr kassen\u00e4rztliche Versorgung https:\/\/www.zi.de\/. Accessed 18 December 2025"},{"key":"3031_CR13","unstructured":"Head of Medicines Agency (HMA). European Medicines Agency (EMA) Guideline on good pharmacovigilance practices (GVP) Module VI \u2013 Collection, management and submission of reports of suspected adverse reactions to medicinal products (Rev 2) (2017) https:\/\/www.ema.europa.eu\/en\/documents\/regulatory-procedural-guideline\/guideline-good-pharmacovigilance-practices-gvp-module-vi-collection-management-submission-reports-suspected-adverse-reactions-medicinal-products-rev-2_en.pdf. Accessed 18 December 2025"},{"key":"3031_CR14","doi-asserted-by":"publisher","unstructured":"Dubrall D, Schmid M, Ale\u0161ik E, Paeschke N, Stingl J, Sachs B (2018) Frequent Adverse Drug Reactions, and Medication Groups under Suspicion Dtsch Arztebl Int. 8;115(23):393\u2013400. https:\/\/doi.org\/10.3238\/arztebl.2018.0393","DOI":"10.3238\/arztebl.2018.0393"},{"key":"3031_CR15","unstructured":"European Medicines Agency EudraVigilance. https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/research-development\/pharmacovigilance-research-development\/eudravigilance. Accessed 18 December 2025"},{"key":"3031_CR16","unstructured":"Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte. ATC-Klassifikation (2024) https:\/\/www.bfarm.de\/DE\/Kodiersysteme\/Klassifikationen\/ATC\/_node.html. Accessed 18 December 2025"},{"key":"3031_CR17","unstructured":"Charite Universit\u00e4tsmedizin Berlin https:\/\/www.embryotox.de\/. Accessed 18 December 2025"},{"key":"3031_CR18","unstructured":"Uniklinikum Erlangen Kinderformularium.DE. https:\/\/kinderformularium.de\/sign_in\/kidsafe. Accessed 18 December 2025"},{"issue":"2","key":"3031_CR19","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s40272-022-00540-z","volume":"25","author":"S Leitzen","year":"2023","unstructured":"Leitzen S, Dubrall D, Toni I, Stingl J, Christ P, K\u00f6berle U, Schmid M, Neubert A, Sachs B (2023) Adverse Drug Reactions in Children: Comparison of Reports Collected in a Pharmacovigilance Project Versus Spontaneously Collected ADR Reports. Paediatr Drugs 25(2):203\u2013215. https:\/\/doi.org\/10.1007\/s40272-022-00540-z","journal-title":"Paediatr Drugs"},{"issue":"1","key":"3031_CR20","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s40264-019-00803-8","volume":"37","author":"T Bergvall","year":"2014","unstructured":"Bergvall T, Nor\u00e9n GN, Lindquist M (2014) vigiGrade: a tool to identify well-documented individual case reports and highlight systematic data quality issues. Drug Saf 37(1):65\u201377. https:\/\/doi.org\/10.1007\/s40264-019-00803-8","journal-title":"Drug Saf"},{"key":"3031_CR21","unstructured":"R Package segmented. https:\/\/cran.r-project.org\/web\/packages\/segmented\/segmented.pdf. Accessed 12.03.2026."},{"key":"3031_CR22","unstructured":"R Package splines. https:\/\/www.rdocumentation.org\/packages\/splines\/versions\/3.6.2. Accessed 12.02.2026."},{"issue":"3","key":"3031_CR23","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1089\/cap.2023.0077","volume":"34","author":"NR S\u00f8ndergaard","year":"2024","unstructured":"S\u00f8ndergaard NR, N\u00f8r\u00f8xe KB, Carlsen AH, Randing SH, Warrer P, Thomsen PH, Clausen L (2024) Switch to Lisdexamfetamine in the Treatment of Attention-Deficit Disorder at a Psychiatric Outpatient Clinic for School-Aged Children: A Danish Cohort Study. J Child Adolesc Psychopharmacol 34(3):137\u2013147. https:\/\/doi.org\/10.1089\/cap.2023.0077","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"3031_CR24","doi-asserted-by":"publisher","DOI":"10.1007\/s00787-025-02791-w","author":"LT Ringeling","year":"2025","unstructured":"Ringeling LT, Srivastava A, Gangapersad RN, Bos JHJ, de Winter BCM, Hak E, Hillegers MHJ, Koch BCP, Schuiling-Veninga CCM, Dierckx B (2025) ADHD medication dispensing trends in Dutch youth before and after the implementation of the Youth Act (2010\u20132022). Eur Child Adolesc Psychiatry doi. https:\/\/doi.org\/10.1007\/s00787-025-02791-wEpub ahead of print","journal-title":"Eur Child Adolesc Psychiatry doi"},{"issue":"6","key":"3031_CR25","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.encep.2025.01.005","volume":"51","author":"A Velay","year":"2025","unstructured":"Velay A, Alexis J, Papinaud L, Domerg C, Ouakil DP, Willig TN, Kerbage H (2025) Evolution of methylphenidate prescriptions in the region of Occitanie, France, from 2013 to 2021. Encephale 51(6):651\u2013659. https:\/\/doi.org\/10.1016\/j.encep.2025.01.005","journal-title":"Encephale"},{"issue":"10","key":"3031_CR26","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1007\/s00787-022-02034-2","volume":"32","author":"AMS S\u00f8rensen","year":"2023","unstructured":"S\u00f8rensen AMS, Wesselh\u00f6eft R, Andersen JH, Reutfors J, Cesta CE, Furu K, Hartz I, Rasmussen L (2023) Trends in use of attention deficit hyperactivity disorder medication among children and adolescents in Scandinavia in 2010\u20132020. Eur Child Adolesc Psychiatry 32(10):2049\u20132056. https:\/\/doi.org\/10.1007\/s00787-022-02034-2","journal-title":"Eur Child Adolesc Psychiatry"},{"issue":"3","key":"3031_CR27","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1177\/1087054721997556","volume":"26","author":"SS Hasan","year":"2022","unstructured":"Hasan SS, Bal N, Baker I, Kow CS, Khan MU (2022) Adverse Drug Reaction Reporting and Prescribing Trends of Drugs for Attention Deficit Hyperactivity Disorder in Primary Care England, 2010\u20132019. J Atten Disord 26(3):467\u2013475. https:\/\/doi.org\/10.1177\/1087054721997556","journal-title":"J Atten Disord"},{"key":"3031_CR28","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s12888-024-05505-9","volume":"24","author":"S Gimbach","year":"2024","unstructured":"Gimbach S, Vogel D, Fried R et al (2024) ADHD medicine consumption in Europe after COVID-19: catch-up or trend change? BMC Psychiatry 24:112. https:\/\/doi.org\/10.1186\/s12888-024-05505-9","journal-title":"BMC Psychiatry"},{"key":"3031_CR29","unstructured":"Mirjam M (2025) ADHS: Mehr Diagnosen durch Social Media? Deutsches \u00c4rztebl 122(4)"},{"issue":"9","key":"3031_CR30","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/S2215-0366(18)30269-4","volume":"5","author":"S Cortese","year":"2018","unstructured":"Cortese S, Adamo N, Del Giovane C et al (2018) Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry 5(9):727\u2013738. https:\/\/doi.org\/10.1016\/S2215-0366(18)30269-4","journal-title":"Lancet Psychiatry"},{"issue":"3","key":"3031_CR31","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1177\/0269881113519509","volume":"28","author":"B Bolea-Alama\u00f1ac","year":"2014","unstructured":"Bolea-Alama\u00f1ac B, Nutt DJ, Adamou M et al (2014) Evidence-based guidelines for the pharmacological management of attention deficit hyperactivity disorder: Update on recommendations from the British Association for Psychopharmacology. J Psychopharmacol 28(3):179\u2013203. https:\/\/doi.org\/10.1177\/0269881113519509","journal-title":"J Psychopharmacol"},{"key":"3031_CR32","unstructured":"DIRECTIVE 2001\/83\/EC OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 6 November 2001 on the Community code relating to medicinal products for human use. https:\/\/eur-lex.europa.eu\/LexUriServ\/LexUriServ.do?uri=CONSLEG:2001L0083:20121116:EN:PDF. Accessed 18 December 2025"},{"key":"3031_CR33","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s40264-021-01137-0","volume":"45","author":"G Candore","year":"2022","unstructured":"Candore G, Monzon S, Slattery J, et a (2022) )l. The Impact of Mandatory Reporting of Non-Serious Safety Reports to EudraVigilance on the Detection of Adverse Reactions. Drug Saf 45:83\u201395","journal-title":"Drug Saf"},{"issue":"3","key":"3031_CR34","doi-asserted-by":"publisher","first-page":"e0247446","DOI":"10.1371\/journal.pone.0247446","volume":"16","author":"S Leitzen","year":"2021","unstructured":"Leitzen S, Dubrall D, Toni I, Stingl J, Schulz M, Schmid M et al (2021) Analysis of the reporting of adverse drug reactions in children and adolescents in Germany in the time period from 2000 to 2019. PLoS ONE 16(3):e0247446. https:\/\/doi.org\/10.1371\/journal.pone.0247446","journal-title":"PLoS ONE"},{"key":"3031_CR35","unstructured":"European Medicines Agency (2024) Annual Report on EudraVigilance for the European Parliament, the Council and the Commission Reporting period: 1 January to 31 December 2024 (2025). https:\/\/www.ema.europa.eu\/system\/files\/documents\/report\/2024-annual-report-eudravigilance-en.pdf. Accessed 18 December 2025"},{"issue":"12","key":"3031_CR36","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1007\/s40264-023-01359-4","volume":"46","author":"S De Germay","year":"2023","unstructured":"De Germay S, Singier A, Salvo F, Pariente A (2023) French Pharmacovigilance Network. Impact of Covid-19 Vaccination on Spontaneous Pharmacovigilance Reporting in France. Drug Saf 46(12):1381\u20131389","journal-title":"Drug Saf"},{"issue":"12","key":"3031_CR37","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1007\/s40264-023-01355-8","volume":"46","author":"P Christ","year":"2023","unstructured":"Christ P, Dubrall D, Schmid M, Sachs B (2023) Comparative Analysis of Information Provided in German Adverse Drug Reaction Reports Sent by Physicians, Pharmacists and Consumers. Drug Saf 46(12):1363\u20131379. https:\/\/doi.org\/10.1007\/s40264-023-01355-8Epub 2023 Nov 21. PMID: 37987966; PMCID: PMC10684666","journal-title":"Drug Saf"},{"issue":"9","key":"3031_CR38","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/S0895-4356(02)00450-X","volume":"55","author":"J Hasford","year":"2002","unstructured":"Hasford J, Goettler M, Munter KH et al (2002) Physicians\u2019 knowledge and attitudes regarding the spontaneous reporting system for adverse drug reactions. J Clin Epidemiol 55(9):945\u2013950","journal-title":"J Clin Epidemiol"},{"key":"3031_CR39","doi-asserted-by":"publisher","unstructured":"Hartnell NR, Wilson JP (2012) Replication of the Weber Effect Using Postmarketing Adverse Event Reports Voluntarily Submitted to the United States Food and Drug Administration. Pharmacotherapy 24(6):743-9. https:\/\/doi.org\/10.1592\/phco.24.8.743.36068. PMID: 15222664","DOI":"10.1592\/phco.24.8.743.36068"},{"issue":"4","key":"3031_CR40","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s40264-014-0150-2","volume":"37","author":"KB Hoffman","year":"2014","unstructured":"Hoffman KB, Dimbil M, Erdman CB, Tatonetti NP, Overstreet BM (2014) The Weber effect and the United States Food and Drug Administration\u2019s Adverse Event Reporting System (FAERS): analysis of sixty-two drugs approved from 2006 to 2010. Drug Saf 37(4):283\u2013294. https:\/\/doi.org\/10.1007\/s40264-014-0150-2","journal-title":"Drug Saf"},{"key":"3031_CR41","doi-asserted-by":"publisher","first-page":"233","DOI":"10.2165\/00002018-200124030-00006","volume":"24","author":"EJ Wallenstein","year":"2001","unstructured":"Wallenstein EJ, Fife D (2001) Temporal Patterns of NSAID Spontaneous Adverse Event Reports. Drug Saf 24:233\u2013237. https:\/\/doi.org\/10.2165\/00002018-200124030-00006","journal-title":"Drug Saf"},{"issue":"4","key":"3031_CR42","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s00228-017-2396-y","volume":"74","author":"K Svendsen","year":"2018","unstructured":"Svendsen K, Halvorsen KH, Vorren S, Samdal H, Garcia B (2018) Adverse drug reaction reporting: how can drug consumption information add to analyses using spontaneous reports? Eur J Clin Pharmacol 74(4):497\u2013504. https:\/\/doi.org\/10.1007\/s00228-017-2396-y","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"3031_CR43","doi-asserted-by":"publisher","first-page":"e20192528","DOI":"10.1542\/peds.2019-2528","volume":"44","author":"ML Wolraich","year":"2019","unstructured":"Wolraich ML, Hagan JF Jr, Allan C, Chan E, Davison D, Earls M, Evans SW, Flinn SK, Froehlich T, Frost J, Holbrook JR, Lehmann CU, Lessin HR, Okechukwu K, Pierce KL, Winner JD, Zurhellen W, SUBCOMMITTEE ON CHILDREN AND ADOLESCENTS WITH ATTENTION-DEFICIT\/HYPERACTIVE DISORDER (2019) Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit\/Hyperactivity Disorder in Children and Adolescents. Pediatrics 44(4):e20192528. https:\/\/doi.org\/10.1542\/peds.2019-2528","journal-title":"Pediatrics"},{"issue":"8","key":"3031_CR44","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1177\/10870547251315601","volume":"29","author":"IL Rapoport","year":"2025","unstructured":"Rapoport IL, Groenman AP (2025) A Review of Sex and Gender Factors in Stimulant Treatment for ADHD: Knowledge Gaps and Future Directions. J Atten Disord 29(8):602\u2013616. https:\/\/doi.org\/10.1177\/10870547251315601","journal-title":"J Atten Disord"},{"key":"3031_CR45","doi-asserted-by":"publisher","first-page":"1208456","DOI":"10.3389\/fphar.2023.1208456","volume":"14","author":"W Wei","year":"2023","unstructured":"Wei W, Chen L, Zhou H, Liu J, Zhang Y, Feng S, Bai Y, Leng Y, Chang E, Huang L (2023) Safety profiles of methylphenidate, amphetamine, and atomoxetine: analysis of spontaneous reports submitted to the food and drug administration adverse event reporting system. Front Pharmacol 14:1208456. https:\/\/doi.org\/10.3389\/fphar.2023.1208456","journal-title":"Front Pharmacol"},{"issue":"5","key":"3031_CR46","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","volume":"29","author":"L Hazell","year":"2006","unstructured":"Hazell L, Shakir SAW (2006) Under-reporting of adverse drug reactions: a systematic review. Drug Saf 29(5):385\u2013396","journal-title":"Drug Saf"}],"container-title":["European Child &amp; Adolescent Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00787-026-03031-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00787-026-03031-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00787-026-03031-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T21:02:27Z","timestamp":1791579747000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00787-026-03031-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,27]]},"references-count":46,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["3031"],"URL":"https:\/\/doi.org\/10.1007\/s00787-026-03031-5","relation":{},"ISSN":["1018-8827","1435-165X"],"issn-type":[{"value":"1018-8827","type":"print"},{"value":"1435-165X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,27]]},"assertion":[{"value":"23 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"DD and MS are supported by the EVAS project, which is founded by the Federal Institute for Drugs and Medical Devices and the Institute for Medical Biometry, Informatics and Epidemiology at the university hospital Bonn. PLP has received speaker honoraria from GSK, Janssen, Medice, Consilium, infectopharm, and Oral B. None of the authors has any commercial association that may pose a conflict of interest in connection with the submitted manuscript.","order":1,"name":"Ethics","label":"Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}}]}}